Cigna’s second-quarter revenue surged 11% to $67.2 billion, primarily driven by strong performance in its Evernorth Health Services segment. Despite a strategic divestiture impacting Cigna Healthcare, the company reaffirmed its 2025 outlook, highlighting disciplined execution and a strategic business mix.
The Cigna Group has once again demonstrated its formidable financial muscle, reporting a robust second quarter for 2025 that saw total revenues surge by 11% to an impressive $67.2 billion.
This significant leap underscores a period of strategic recalibration and focused growth for the global health giant, even as it navigates the complex currents of the healthcare landscape.
Shareholders’ net income remained steady at $1.5 billion, translating to $5.71 per share, a modest gain from the $5.45 per share recorded in the same period last year, reflecting diligent capital management alongside operational consistency.
At the heart of Cigna’s buoyant performance lies Evernorth Health Services, the company’s integrated health services segment.
This division, encompassing pharmacy benefit management, specialty pharmacy, and care services, has emerged as the unequivocal growth engine.
Its adjusted revenues climbed a remarkable 17% year-over-year, propelled by strong organic growth, the deepening of existing client relationships, and the successful onboarding of new business.
This surge was particularly evident in the specialty pharmacy sector, where Cigna has clearly capitalized on the increasing demand for complex drug therapies and the growing adoption of biosimilars.
The pre-tax adjusted income from operations for Evernorth also saw a healthy 5% increase, testament to its ability to drive both top-line expansion and bottom-line efficiency through affordability improvements and strategic initiatives.
The narrative for Cigna Healthcare, the company’s traditional health insurance arm, is more nuanced, largely shaped by a significant strategic divestiture.
On March 19, 2025, Cigna completed the sale of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, and CareAllies businesses to Health Care Services Corporation (HCSC).
This transaction, while streamlining Cigna’s portfolio, naturally impacted direct year-over-year comparisons.
Consequently, Cigna Healthcare’s adjusted revenues appeared to decrease by 18%.
However, a closer look reveals that excluding the impact of this divestiture, revenues for the segment actually increased by a respectable 7%.
This underlying growth was primarily driven by premium rate increases, a necessary adjustment to cover anticipated rises in medical costs.
Despite this underlying revenue growth, Cigna Healthcare faced headwinds in its profitability, with adjusted income from operations decreasing by 9%.
This was largely attributed to a higher Medical Care Ratio (MCR), which climbed to 83.2% in the second quarter of 2025, up from 82.3% in the prior year.
A rising MCR indicates that a larger portion of premium revenue is being spent on medical claims, signaling increased healthcare utilization or higher costs, particularly noted in higher stop loss medical costs.
This metric serves as a critical barometer for the profitability of an insurer’s core business, and Cigna’s slightly elevated MCR suggests ongoing vigilance will be required to manage claims expenses effectively in a dynamically evolving healthcare landscape.
Beyond the segment-specific details, Cigna’s overall operational discipline shines through in its improved SG&A (selling, general, and administrative) expense ratio.
The GAAP SG&A ratio decreased to 5.1% from 6.1% in the prior year, with the adjusted ratio similarly falling to 4.9% from 6.0%.
This reduction reflects a favorable business mix shift towards the higher-revenue-generating Evernorth services and strong overall revenue growth, indicating effective cost management and scaling efficiencies across the enterprise.
The company’s customer relationships also paint a picture of strategic repositioning.
While total medical customers saw a 6% decrease to 18.0 million due to the HCSC transaction, Cigna emphasized that excluding this impact, the number remained consistent.
More importantly, total pharmacy customers grew by 3% to 121.9 million, reinforcing Evernorth’s expanding reach and market penetration.
Overall customer relationships stood at 182.2 million, increasing by 2% from the end of 2024 when the HCSC transaction’s effects are factored out.
David M. Cordani, chairman and CEO of The Cigna Group, encapsulated the company’s philosophy, stating, “Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients enables us to deliver meaningful value.
Our performance in the second quarter reflects our disciplined execution and the strength of our business mix.”
His words resonate with the company’s strategic pivot, leveraging its integrated capabilities to offer a broader spectrum of health solutions beyond traditional insurance.
Looking ahead, Cigna has reaffirmed its 2025 outlook for adjusted income from operations of at least $29.60 per share.
This unwavering confidence in its full-year projections, despite the ongoing shifts within its business segments and the broader economic environment, speaks volumes about management’s belief in its strategic direction and operational resilience.
The emphasis on Evernorth as a primary growth driver, coupled with a disciplined approach to managing its Cigna Healthcare segment post-divestiture, positions the company to continue its trajectory as a diversified global health services provider.
The second quarter results are not just numbers; they are a clear indicator of a company actively shaping its future, focusing on high-growth areas while prudently managing its established lines of business.
